findmyKOL

Marc Feinstein, MD

Basic profile

Memorial Sloan Kettering Cancer Center

ORCIDNone on fileNPI
RegionNew York, NY · NortheastSpecialtyPulmonary DiseaseFocusRespiratory
Last active 2022findmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2022Online presenceNot yet checkedPaymentsNone reportedNIH funding2001–2002Why? →

Marc Feinstein is a Respiratory physician affiliated with Memorial Sloan Kettering Cancer Center. OpenAlex indexes 33 publications with 844 citations (h-index 15); ClinicalTrials.gov lists 1 registered study matched to this name.

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
33publications

Distinct works indexed by OpenAlex.

844citations

Total citations across indexed works.

15h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
1clinical trials

Investigator role on registered studies.

View trials
1NIH grants · 2001–2002

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

1275 York Ave
New York, NY 100216007

Telephone

212-639-2000

Registry record last updated 7 Apr 2015.

View the NPPES registry record

Clinical trials

Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Respiratory

    79.2%
    Corticosteroid43.3%
    Trelegy Ellipta34%Breo Ellipta32%Budesonide-Formoterol Fumarate13%Symbicort12%Fluticasone Propionate10%
    Part D<11 patients
    beta2-Adrenergic Agonist19.1%
    Albuterol Sulfate Hfa78%Ventolin Hfa22%
    Part D<11 patients

    + 2 more classes in this area

  • Metabolism & gastrointestinal

    13.7%
    Corticosteroid10.9%
    Prednisone100%
    Part D21 patients
    Proton pump inhibitor2.8%
    Omeprazole100%
    Part D<11 patients
  • Anti-infectives

    7.1%
    Macrolide Antimicrobial4.5%
    Azithromycin100%
    Part D12 patients
    Short-acting sulfonamides2.6%
    Sulfamethoxazole-Trimethoprim100%
    Part D<11 patients
Where care is delivered (Part B)19% facility · 81% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

1 NIH research award on record, funded 20012002 per NIH RePORTER. The latest:

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”